Neurocrine Biosciences (NBIX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Neurocrine Biosciences (NBIX) do?
Neurocrine Biosciences Inc (NBIX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells oral prescription therapies for involuntary movement disorders, chorea, and rare endocrine conditions. Discovers and commercializes targeted pharmaceutical treatments for neurological, endocrine, and psychiatric disorders. It is worth $15.85B on the market and sold $3.70B over the last year.
- Market cap
- $15.85B
- P/E ratio
- 23.2×
- Annual sales
- $3.70B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 13, 2026
Brands and businesses behind NBIX
- Ingrezza: Generates revenue by treating adult tardive dyskinesia and chorea linked to Huntington disease through daily oral capsules.
- Ongentys: Earns revenue by providing an oral adjunctive therapy for patients with Parkinson disease experiencing motor fluctuations.
NBIX’s flags, in plain English
Each flag is a number from Neurocrine Biosciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Low debt
Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 96.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Worth a Look
A single drug, Ingrezza, generates the vast majority of total commercial revenue. Something here could change the picture, so it is worth reading next to the good news.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about NBIX
How big is Neurocrine Biosciences?
Neurocrine Biosciences’ market cap is $15.85B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.70B: what customers paid the company over the last year, before any costs.
What is NBIX’s P/E ratio?
NBIX’s P/E ratio is 23.2×. Investors pay about 23.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with NBIX?
The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Neurocrine Biosciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NBIX’s filings on SEC.gov. The Margin Monkey is research, not advice.
